Certara Services Archives

Case Study

Dose Optimization Using Population PK for an Orphan Drug

RAPALIMUS® Tablets (sirolimus) is Nobelpharma’s orphan drug developed from an oral medication that is sold…

CertaraNovember 17, 2021

Case Study

Defining path-to-market strategy through a data-driven and scientific approach

How Certara supported a gene therapy manufacturer by using a selection of gateway and value…

CertaraOctober 28, 2021

White Paper

Using Real-world Evidence to Advance Market Access for New Therapeutics

CertaraSeptember 29, 2021

On-Demand Webinar

The Scary Future of Rare Disease Management

In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…

CertaraSeptember 23, 2021

Blog

Succeeding in Value Communication: Introduction

Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…

CertaraAugust 5, 2021

Video

What is BaseCase?

Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…

CertaraJuly 20, 2021

Blog

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…

CertaraJune 18, 2021

On-Demand Webinar

Three Pathways have emerged in Innovative Access Agreements

The days of simply determining the market demand for a new drug as a function…

CertaraJune 11, 2021

On-Demand Webinar

Outcomes Based Agreements

The days of simply determining the market demand for a new drug as a function…

CertaraJune 11, 2021

On-Demand Webinar

Stakeholder perspectives: current and potential benefits

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

CertaraMay 26, 2021

Certara Services

Dose Optimization Using Population PK for an Orphan Drug

Defining path-to-market strategy through a data-driven and scientific approach

Using Real-world Evidence to Advance Market Access for New Therapeutics

The Scary Future of Rare Disease Management

Succeeding in Value Communication: Introduction

What is BaseCase?

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

Three Pathways have emerged in Innovative Access Agreements

Outcomes Based Agreements

Stakeholder perspectives: current and potential benefits

Newsletter sign up

Quick links

Solutions

Contact